Clinical Trial 41896

Chattanooga, TN 37421


Effective treatment of C. diff infections is critical, but how do we prevent the problem of recurrences?

Recurrence of Clostridium difficile infection (CDI) is a key unmet medical need in the management of CDI:

  • Occurs in up to 30% of patients following initial therapy
  • Significant burden on patients due to increased morbidity and diminished quality of life
  • Associated with an increased risk of further recurrent episodes and an increase in severity

Learn how to participate in the Ri-CoDIFy study investigating an antibiotic has the potential to not only effectively treat CDI but also to reduce disease recurrence typically seen with standard of care antibiotic treatments.

If you are interested in participating in our clostridium difficile study, please fill out the form below.

Qualified Participants Must:

• Be at least 18 years of age, at the time of signing the informed consent
• Have signs and symptoms of CDI including diarrhea such that in the Investigator's opinion CDI antimicrobial therapy is required

*Other qualifications may apply.

Qualified Participants May Receive:

Qualified participants will receive:

  • Study-related medication at no cost
  • Study-related medical exams at no cost
  • Compensation for time and travel

Clinical trials are medical research studies designed to test the safety and/or effectiveness of new investigational drugs, devices, or treatments in humans. These studies are conducted worldwide for a range of conditions and illnesses. Learn more about clinical research and participating in a study at About Clinical Trials.